These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 36835356

  • 1. Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease.
    Dinur T, Bauer P, Beetz C, Cozma C, Becker-Cohen M, Istaiti M, Rolfs A, Skrahina V, Zimran A, Revel-Vilk S.
    Int J Mol Sci; 2023 Feb 15; 24(4):. PubMed ID: 36835356
    [Abstract] [Full Text] [Related]

  • 2. Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?
    Dinur T, Bauer P, Beetz C, Kramp G, Cozma C, Iurașcu MI, Becker-Cohen M, Istaiti M, Rolfs A, Zimran A, Revel-Vilk S.
    Int J Mol Sci; 2022 Jan 30; 23(3):. PubMed ID: 35163551
    [Abstract] [Full Text] [Related]

  • 3. Detection of glucosylsphingosine in dried blood spots for diagnosis of Gaucher disease by LC-MS/MS.
    Tang C, Jia X, Tang F, Liu S, Jiang X, Zhao X, Sheng H, Peng M, Liu L, Huang Y.
    Clin Biochem; 2021 Jan 30; 87():79-84. PubMed ID: 33188770
    [Abstract] [Full Text] [Related]

  • 4. Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease.
    Hurvitz N, Dinur T, Becker-Cohen M, Cozma C, Hovakimyan M, Oppermann S, Demuth L, Rolfs A, Abramov A, Zimran A, Revel-Vilk S.
    Int J Mol Sci; 2019 Jun 21; 20(12):. PubMed ID: 31234327
    [Abstract] [Full Text] [Related]

  • 5. Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations.
    Dinur T, Grittner U, Revel-Vilk S, Becker-Cohen M, Istaiti M, Cozma C, Rolfs A, Zimran A.
    Int J Mol Sci; 2021 Jul 19; 22(14):. PubMed ID: 34299318
    [Abstract] [Full Text] [Related]

  • 6. Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots.
    Cozma C, Cullufi P, Kramp G, Hovakimyan M, Velmishi V, Gjikopulli A, Tomori S, Fischer S, Oppermann S, Grittner U, Bauer P, Beetz C, Rolfs A.
    Int J Mol Sci; 2020 Jun 27; 21(13):. PubMed ID: 32605119
    [Abstract] [Full Text] [Related]

  • 7. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.
    Elstein D, Mellgard B, Dinh Q, Lan L, Qiu Y, Cozma C, Eichler S, Böttcher T, Zimran A.
    Mol Genet Metab; 2017 Sep 27; 122(1-2):113-120. PubMed ID: 28851512
    [Abstract] [Full Text] [Related]

  • 8. Long- and Short-Term Glucosphingosine (lyso-Gb1) Dynamics in Gaucher Patients Undergoing Enzyme Replacement Therapy.
    Dubiela P, Szymanska-Rozek P, Hasinski P, Lipinski P, Kleinotiene G, Giersz D, Tylki-Szymanska A.
    Biomolecules; 2024 Jul 12; 14(7):. PubMed ID: 39062556
    [Abstract] [Full Text] [Related]

  • 9. An observational study to investigate the relationship between plasma glucosylsphingosine (lyso-Gb1) concentration and treatment outcomes of patients with Gaucher disease in Japan.
    Ida H, Watanabe Y, Sagara R, Inoue Y, Fernandez J.
    Orphanet J Rare Dis; 2022 Nov 03; 17(1):401. PubMed ID: 36329499
    [Abstract] [Full Text] [Related]

  • 10. Glucosylsphingosine (Lyso-Gb1): An Informative Biomarker in the Clinical Monitoring of Patients with Gaucher Disease.
    Gayed MM, Jung SH, Huggins E, Rodriguez-Rassi E, DeArmey S, Kishnani PS, Stiles AR.
    Int J Mol Sci; 2022 Nov 29; 23(23):. PubMed ID: 36499264
    [Abstract] [Full Text] [Related]

  • 11. Glucosylsphingosine is a key biomarker of Gaucher disease.
    Murugesan V, Chuang WL, Liu J, Lischuk A, Kacena K, Lin H, Pastores GM, Yang R, Keutzer J, Zhang K, Mistry PK.
    Am J Hematol; 2016 Nov 29; 91(11):1082-1089. PubMed ID: 27441734
    [Abstract] [Full Text] [Related]

  • 12. Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review.
    Revel-Vilk S, Fuller M, Zimran A.
    Int J Mol Sci; 2020 Sep 28; 21(19):. PubMed ID: 32998334
    [Abstract] [Full Text] [Related]

  • 13. A Brazilian Rare-Disease Center's Experience with Glucosylsphingosine (lyso-Gb1) in Patients with Gaucher Disease: Exploring a Novel Correlation with IgG Levels in Plasma and a Biomarker Measurement in CSF.
    Vernet Machado Bressan Wilke M, Iop GD, Faqueti L, Lemos da Silva LA, Kubaski F, Poswar FO, Michelin-Tirelli K, Randon D, Borelli WV, Giugliani R, Schwartz IVD.
    Int J Mol Sci; 2024 Mar 01; 25(5):. PubMed ID: 38474117
    [Abstract] [Full Text] [Related]

  • 14. Expanding the clinical utility of glucosylsphingosine for Gaucher disease.
    Saville JT, McDermott BK, Chin SJ, Fletcher JM, Fuller M.
    J Inherit Metab Dis; 2020 May 01; 43(3):558-563. PubMed ID: 31707742
    [Abstract] [Full Text] [Related]

  • 15. Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review.
    Giuffrida G, Markovic U, Condorelli A, Calafiore V, Nicolosi D, Calagna M, Grasso S, Ragusa MTV, Gentile J, Napolitano M.
    Orphanet J Rare Dis; 2023 Feb 13; 18(1):27. PubMed ID: 36782327
    [Abstract] [Full Text] [Related]

  • 16. Glucosylsphingosine Causes Hematological and Visceral Changes in Mice-Evidence for a Pathophysiological Role in Gaucher Disease.
    Lukas J, Cozma C, Yang F, Kramp G, Meyer A, Neßlauer AM, Eichler S, Böttcher T, Witt M, Bräuer AU, Kropp P, Rolfs A.
    Int J Mol Sci; 2017 Oct 20; 18(10):. PubMed ID: 29053611
    [Abstract] [Full Text] [Related]

  • 17. Long-Term Evaluation of Biomarkers in the Czech Cohort of Gaucher Patients.
    Malinová V, Poupětová H, Řeboun M, Dvořáková L, Reichmannová S, Švandová I, Murgašová L, Kasper DC, Magner M.
    Int J Mol Sci; 2023 Sep 22; 24(19):. PubMed ID: 37833892
    [Abstract] [Full Text] [Related]

  • 18. Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF Study.
    Curado F, Rösner S, Zielke S, Westphal G, Grittner U, Skrahina V, Alasel M, Malik AM, Beetz C, Böttcher T, Barel G, Sah AP, Dinur T, Anjum N, Ichraf Q, Kriouile Y, Hadipour Z, Hadipour F, Revel-Vilk S, Cozma C, Hartkamp J, Cheema H, Zimran A, Bauer P, Rolfs A, LYSO-PROOF Study Group.
    Diagnostics (Basel); 2023 Aug 30; 13(17):. PubMed ID: 37685353
    [Abstract] [Full Text] [Related]

  • 19. Metabolomic Study Using Time-of-Flight Mass Spectrometry Reveals Novel Urinary Biomarkers for Gaucher Disease Type 1.
    Menkovic I, Boutin M, Alayoubi A, Curado F, Bauer P, Mercier FE, Auray-Blais C.
    J Proteome Res; 2022 May 06; 21(5):1321-1329. PubMed ID: 35349295
    [Abstract] [Full Text] [Related]

  • 20. Identification of a Reliable Biomarker Profile for the Diagnosis of Gaucher Disease Type 1 Patients Using a Mass Spectrometry-Based Metabolomic Approach.
    Menkovic I, Boutin M, Alayoubi A, Mercier FE, Rivard GÉ, Auray-Blais C.
    Int J Mol Sci; 2020 Oct 23; 21(21):. PubMed ID: 33114153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.